濮阳东方妇科医院做人流收费非常低濮阳东方医院割包皮手术好不好,濮阳东方医院治疗阳痿靠谱,濮阳东方医院看阳痿收费非常低,濮阳东方医院治疗阳痿收费低,濮阳东方男科医院收费不高,濮阳东方医院男科收费便宜,濮阳东方看男科口碑好很不错

SINGAPORE, July 3 (Xinhua) -- The over 60 nursing homes in Singapore, especially those run by voluntary welfare organizations, are facing a bed crunch, local daily Straits Times reported on Sunday.The newspaper found in a check with 20 homes that more than half of the nursing homes were running at full or almost full capacity. Homes run by voluntary welfare organizations, where there are subsidized beds, have long waiting lists.The average waiting time for a bed in nursing homes run by voluntary welfare organizations rose from 50 days in 2008 to about 60 days early last year, the newspaper said.It is easier to get a bed in a privately run home, though only slightly and if you can afford it. Econ Healthcare Group, which runs eight nursing homes in Singapore, said the occupancy rate is 99 percent and it has waiting lists of up to 20 people at some branches.Demand for nursing homes in the city state can only grow given the aging population. By 2030, the number of people aged 65 or above is projected to reach 900,000, or one in every five residents.

SAN FRANCISCO, Sept. 6 (Xinhua)-- Yahoo on Tuesday fired Chief Executive Officer Carol Bartz and replaced her temporarily with the company's chief financial officer."On behalf of the entire board, I want to thank Carol for her service to Yahoo during a critical time of transition in the company's history, and against a very challenging macro-economic backdrop," said Yahoo Chairman Roy Bostock in a news release.The Yahoo Board of Directors appointed CFO Timothy Morse as interim CEO who will manage the company's day-to-day operations until a permanent chief executive is chosen.Carol Bartz, chief executive of Internet company Yahoo Inc, is shown in this undated publicity photo released to Reuters January 13, 2009. Before Yahoo's formal announcement, several news organizations and tech blogs posted an email reportedly from Bartz sent from her iPad to all employees of the company."To all, I am very sad to tell you that I've just been fired over the phone by Yahoo's Chairman of the Board. It has been my pleasure to work with all of you and I wish you only the best going forward."Bartz, 63, took over the Yahoo CEO role from co-founder Jerry Young in January 2009, when the company was struggling to stay competitive and profitable in a market dominated by Google. However, Yahoo never reached the heights she had foreseen.In the most recent quarterly earnings report in June, Yahoo reported net revenue of 1.1 billion U.S. dollars, down 5 percent from last year.Morse, 42, was hired as executive vice president and CFO at Yahoo in July 2009. "It is an honor to be selected for this role," he said in a statement Tuesday.Yahoo said it is starting a search for a new permanent CEO and plans to hire a "nationally recognized executive search firm" to assist in the effort.

UNITED NATIONS, June 8 (Xinhua) -- Marking 30 years of the HIV- AIDS pandemic, scores of heads of state and government and ministers took to the UN General Assembly podium on Wednesday to list their country's accomplishments and list challenges in the battle.The General Assembly High Level Meeting on AIDS is taking place 10 years after the UN Special Session on HIV/AIDS and also marks five years since signing of the Political Declaration in which UN member states committed to moving towards universal access to HIV prevention, treatment, care and support.UN Secretary-General Ban Ki-moon UN recalled how three decades ago AIDS was spreading while "Today, we have a chance to end this epidemic once and for all."Now, instead of fear, there is hope, he said."Today, HIV is on a steep decline in some of the most affected countries. Countries like Ethiopia, South Africa, Zambia and Zimbabwe," he said. "They had the largest epidemics in the world, and they have cut infection rates by one quarter.""Globally, more than 6 million people now get treatment," Ban said. "All of these advances come thanks to you and the commitments you made, first 10 years ago and then again in 2006. Today, the challenge has changed. Today, we gather to end AIDS."However, President Joseph Deiss of the General Assembly said 10 million people still have no access to treatment and far too many people were still being infected, adding it was necessary to continue complementary and closely-linked prevention, treatment, care and support measures."We have reached a critical moment in time," he said. "We must take a holistic approach and integrate the response to AIDS into broader development programs."Michel Sidibe, executive director of the Joint UN Program on HIV/AIDS (UNAIDS), recalled how 30 years the disease was called the gay plague and slime disease. People were afraid of each other and there was no hope."This image should not disappear. It is part of our history," he said.Sidibe said the AIDS movement was the story of a people breaking the conspiracy of silence, demanding equity and dignity, confronting societies'wrongs, seizing their rights, and making a passionate call for social justice. Since then, a compact had been made between the global North and the South, which had produced lifesaving results.Now, More than 6.6 million people are being treated in low- and middle- income countries, he said, pointing out that since the initial success stories in Uganda and Thailand 56 countries, including 36 in Africa, have been able to stabilize the epidemic and reduce the number of infections significantly.Infections have been reduced by 35 percent in South Africa and by more than half in India, the UNAIDS chief said. In China, the HIV mortality rate had fallen by 64 percent, Sidibe said. Many other countries had reached universal access to treatment.He voiced what was repeated several times, and that was a call for "a transformational agenda" of "zero infections, zero discrimination and zero AIDS-related deaths."To put a personal face on the disease, a woman from Ukraine openly living with HIV, Tetyana Afansiadi, told her story to the delegates.She told how she had been living with HIV and using drugs for 13 years, had hepatitis C for almost 11 years but now has a husband and an 8-year-old son. Neither have HIV.Three years ago she took part in a drug therapy program that has enabled her to live, work, and take care of her son."Drug dependency and HIV-infection require treatment, not prosecution," she said.Given that opioid substitution therapy in her home city had changed the lives of people like her, it was time to stop refusing antiretroviral treatment to people who used drugs.While the heads of states and government and ministers, usually those heading up health departments, spoke in the General Assembly hall under bright lights, scores more of delegates attended five panel sessions and about 40 individual side events.Some samplings from the spotlighted dark-green podium in the great hall:President Paul Kagame of Rwanda, said, "It is time to galvanize member states to commit to a transformative agenda that overcomes the barriers to an effective, equitable and sustainable response to HIV and AIDS."Jose Angel Cordova Villalobos, health minister of Mexico, called for states to implement friendly, non-discriminatory healthcare systems as well as sex education in order to prevent the spread of HIV/AIDS."To achieve this, we call to all the countries congregated here today in order that your actions are based in the framework of respect to the human rights and focusing on gender equity, that allow to consolidate an effective response to the HIV/AIDS without stigmas, discrimination, homophobia, transphobia; as well as any type of violence," he said, referring, in part, to transsexuals.The vice president of Mauritius, Monique Bellepeau, said, "The adverse impact of the AIDS epidemic on the socioeconomic progress, particularly in the developing countries, dictates that there is no time for complacency."She added, "After wrestling with AIDS for the past three decades, we are today equipped with a vast body of knowledge and various new tools to urgently complete the task. No less than strict prevention efforts and universal access to treatment, care and support are required."The speeches continue Thursday and on the final day of the three-day meeting, UN member states are expected to adopt a declaration to guide country responses to HIV over the next five years.

UNITED NATIONS, Sept. 19 (Xinhua) -- As the UN on Monday pursued the world's top killer -- non-communicable diseases (NCDs) -- a leading doctor from the World Health Organization (WHO) called for preventative measures on such chronic diseases to be placed higher on the international agenda."It's not a choice of dealing with it or not, it's an absolute fundamental imperative for development," said Dr. Douglas Bettcher, WHO's director for the Tobacco Free Initiative, told Xinhua in a recent telephone interview.With NCDs already claiming 36 million lives a year -- nearly 100,000 people a day -- the UN Geneva-based health agency, WHO warns that deaths from chronic diseases will continue to climb even faster, amounting to 52 million deaths by 2030.As world leaders on Monday kicked off a two-day high-level meeting to enact a roadmap to attack diseases like cancer, diabetes, heart and lung diseases, it is hoped that the summit on NCDs, which is being called a "once in a generation opportunity," moves to become a "worldwide priority," Bettcher said.Marking the second time in its history that the United Nations General Assembly has ever put a global disease on the table, health experts and world leaders from 193 nations met to avert what the UN has declared a "public health emergency in slow motion. ""It's a make it or break it time for moving forward this very important agenda at this time of global financial crisis," said Bettcher.Calling NCDs the top global killer "by a long shot," Bettcher attributed such rises in deaths partly to the aging of the world's population, rapid urbanization and increased exposure to risk factors, particularly in low-and middle-income countries."This is a landmark meeting," said UN Secretary-General Ban Ki- moon at the opening of the unprecedented meeting. "Three out of every five people on earth die from the diseases that we gather here to address."The last time the UN looked at a health issue under the global microscope on such a high-level was almost a decade ago.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.